propafenone has been researched along with Arrhythmia in 233 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias." | 10.17 | [Propafenone and flecainide in the therapy of ventricular arrhythmias]. ( Davini, A; Lattanzi, F; Paci, A; Paperini, L; Reisenhofer, B; Squarcini, G; Topi, A; Topi, PL, 1995) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 9.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 9.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "Multivariate regression analysis of spontaneous arrhythmia variability and of different clinical variables to determine the short and long-term efficacy and safety of propafenone." | 9.07 | Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. ( Furtwängler, A; Geibel, A; Hohnloser, S; Just, H; Meinertz, T; Olschewski, M; Zehender, M, 1992) |
| "A double-blind, placebo-controlled trial comparing the antiarrhythmic effects of lidocaine (given intravenously as a bolus injection of 100 mg followed by an infusion of 2 mg min-1) and propafenone (given as a bolus of 105 mg followed by 300 mg orally every 8 h) was conducted in the first 24 h following acute myocardial infarction." | 9.06 | A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. ( Atallah, G; Ferry, S; Kirkorian, G; Marchand, A; Mathieu, MP; Moleur, P; Stahl, C; Touboul, P; Vrancea, F; Zoheir, F, 1988) |
| "A placebo-controlled single-blind study was performed to evaluate the efficacy of oral propafenone on stable potentially malignant ventricular tachyarrhythmias in 13 patients who had suffered a myocardial infarction two months or longer before the trial." | 9.06 | [Efficacy of propafenone in the treatment of ventricular hyperkinetic arrhythmias in subjects with a history of myocardial infarction]. ( Carratino, L; De Caro, E; Ferroni, A; Vecchio, C; Zoni Berisso, M, 1987) |
| "We studied the efficacy of propafenone in 16 patients (pts) with exercise-induced ventricular arrhythmias (VA)." | 9.06 | The efficacy of propafenone on exercise-induced ventricular arrhythmias. ( Argyrakis, S; Cokkinos, DV; Hatzisavvas, J; Papantonakos, A; Perrakis, C, 1987) |
| "A placebo-controlled, randomized, double-blind, crossover study was performed in 14 patients with chronic, resistant, ventricular arrhythmias in order to evaluate the efficacy and safety of two new antiarrhythmic agents, propafenone and aprindine." | 9.05 | [Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo]. ( Amici, R; Ciampani, N; Costantini, C; Mocchegiani, R; Pigini, G; Purcaro, A, 1983) |
| "Propafenone, a new antiarrhythmic agent, was utilized in 30 patients with diverse heart disease who presented with sustained hemodynamically unstable ventricular arrhythmia." | 9.05 | Propafenone: a new agent for ventricular arrhythmia. ( Lown, B; Podrid, PJ, 1984) |
| "Propafenone, a new class I antiarrhythmic drug, given as a bolus injection followed by oral medication, or lidocaine were given to 20 consecutive patients admitted with chest pain suggesting acute myocardial infarction and showing high grades, i." | 9.05 | Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. ( Ericsson, CG; Eriksson, S; Olsson, G; Rehnqvist, N; Svensson, G, 1984) |
| "In 15 patients with ventricular arrhythmias without previous treatment the effectiveness of 2-amino-2',6'-dimethylpropionanilide (tocainide, Xylotocan) and propafenone was compared in a cross-over-trial." | 9.05 | [Comparative studies of tocainide and propafenone in the treatment of ventricular arrhythmias]. ( Gebhardt, A; Hilpert, P; Schmuderer, R, 1984) |
| "The efficacy of propafenone hydrochloride, a new antiarrhythmic agent, was evaluated in the treatment of chronic stable ventricular arrhythmias." | 9.05 | Oral propafenone in the suppression of chronic stable ventricular arrhythmias. ( Kawalsky, DL; Myburgh, DP; Pincus, DR; Schamroth, CL; Schamroth, L; Scholtz, ME, 1985) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 8.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias." | 8.79 | Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. ( Boriani, G; Capucci, A, 1995) |
| "In children, supraventricular tachycardia is the most common form of arrhythmia, and propafenone is an effective class Ic antiarrhythmic agent used in this population." | 8.12 | Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia. ( Hsieh, YT; Huang, CF; Lin, CH; Lin, SC; Lin, YS; Liu, LY; Shen, LJ, 2022) |
| "We present two cases of proarrhythmia after propafenone treatment." | 7.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| "To study the influence of propafenone associated with propofol on myocardial contractility (dP/dt and heart rate), coronary flow, and the incidence of arrhythmia in isolated rat hearts." | 7.72 | Effects of propafenone associated with propofol on myocardial contractility, heart rate, coronary flow, and the incidence of arrhythmia in isolated hearts of rats. ( Assis, NL; do Valle, GG; Garcia, SL; Gomes, OM, 2004) |
| "To determine the effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia." | 7.71 | Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia. ( Cai, WM; Chen, B; Huang, YZ; Xu, J; Zhang, FM; Zhang, YD, 2002) |
| "Tiracizine a new antiarrhythmic drug class Ia was tested in a open crossover study in a group of 46 patients with more than 2500 ventricular extrasystoles per 24 hours or with ventricular arrhythmias III or a higher Lown class." | 7.68 | [Tiracizine in the treatment of ventricular arrhythmia (preliminary study)]. ( Bytesník, J; Groch, L; Krausová, R; Stejfa, M; Zeman, K, 1993) |
| "One hundred and fourteen patients were included in an open multicenter trial of the prevention of atrial arrhythmias by propafenone and of the tolerability of this anti-arrhythmic agent after a year." | 7.68 | [Efficacy and tolerance of propafenone in the prevention after a year of recurrent atrial arrhythmia. Results of a multicenter study of 114 patients]. ( Maarek-Charbit, M; Motté, G; Sirinelli, A, 1992) |
| "105 sequential patients with ventricular arrhythmias in a basal ECG-H recording, that were evaluated within 1 year with a new recording on amiodarone or propafenone, without major clinical events or therapeutic changes between the two recordings." | 7.68 | [Amiodarone and propafenone: evaluation using serial Holter recordings in patients with ventricular arrhythmia]. ( Adragão, P; Bonhorst, D; Seabra-Gomes, R; Ventosa, A, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 7.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone." | 7.67 | Propafenone for the treatment of severe ventricular arrhythmias. ( Bar-Shlomo, B; Boroomand-Rashti, K; Rabkin, SW; Rotem, CE, 1984) |
| "The electrophysiological effects of lidocaine (L) and propafenone (P) in chronic myocardial infarction in relation to tissue drug concentrations (TDC) are unknown." | 7.67 | Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations. ( Agarwal, JB; Bracchetti, D; Helfant, RH; Naccarella, FF; Weintraub, WS, 1984) |
| "Propafenone disposition kinetics were studied after intravenous and oral doses in patients with ventricular arrhythmias." | 7.67 | Propafenone disposition kinetics in cardiac arrhythmia. ( Connolly, S; Harrison, DC; Kates, RE; Lebsack, C; Winkle, RA, 1984) |
| "Antiarrhythmic effects of three new drugs, propafenone, tocainide, and SUN 1165, were examined using three canine ventricular arrhythmia models, i." | 7.67 | Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. ( Hashimoto, K; Ishii, M; Komori, S; Mitsuhashi, H, 1985) |
| "The antiarrhythmic efficacy of Propafenone (PF) was evaluated in 24 patients with ventricular hyperkinetic arrhythmias by means of 24-hour Holter monitoring." | 7.67 | [Propafenone in ventricular hyperkinetic arrhythmias. Dynamic ECG evaluation of the acute oral test and short-term treatment]. ( Cappiello, E; Garimoldi, M; Pirastu, A; Sala, R; Sghirinzetti, M; Terranova, P, 1986) |
| "The purpose of our study was to evaluate the therapeutic and preventive action of propafenone on ventricular hyperkinetic arrhythmias (VHAs)." | 7.67 | [Medium term study of the efficacy of propafenone in the treatment of hyperkinetic ventricular arrhythmia]. ( Cairo, GF; Mascelli, G; Zangara, A; Zanni, PP, 1989) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 7.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "Thirty children aged from 3 months to 20 years were treated with propafenone 250 to 650 mg/m2 divided into 2 to 4 daily doses, for a mean period of 14 months (range: 4 days to 5 years); 8 had chronic atrial tachycardia, 9 had junctional arrhythmia and 13 had ventricular arrhythmia." | 7.67 | [Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases]. ( Batisse, A; Coumel, P; Do Ngoc, D; Fidelle, J; Loth, P; Lucet, V; Sidi, D; Villain, E; Vrancea, F, 1987) |
| "Thirty-two men with chronic ventricular arrhythmias responded to propafenone, a new potent antiarrhythmic agent, in short-term trials with 85% or greater reduction of total ventricular premature complexes (VPCs) per hour, 95% or greater reduction of ventricular couplets (VCs) per hour, and 100% abolition of ventricular tachycardia (VT) beats per 24 hours." | 7.67 | Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. ( Baker, BJ; de Soyza, N; Dinh, H; Murphy, ML, 1988) |
| "The efficacy of Propafenone to prevent exercise-induced ventricular arrhythmias (EIVA) has been studied in eleven patients affected by ischemic heart disease." | 7.67 | [Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy]. ( Arrigo, F; Giannetto, M; Luzza, F; Oreto, G; Patané, S; Virga, T, 1987) |
| "During treatment with the class Ic antiarrhythmic agent propafenone, the drug appeared to cause malignant ventricular tachyarrhythmias in five patients." | 7.67 | Malignant ventricular tachyarrhythmias in association with propafenone treatment. ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "Diprafenone is a new antiarrhythmic agent with a dominant local anesthetic action and additional beta-sympathicolytic activity." | 6.66 | [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone]. ( Geibel, A; Hohnloser, S; Just, H; Landsrath, C; Meinertz, T; Zehender, M, 1988) |
| "Propafenone is a new class Ic antiarrhythmic compound with a broad pharmacologic profile." | 6.66 | Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose-ranging study. ( Guerrero, J; Kaplinsky, E; Kirsten, E; Singh, BN, 1988) |
| "Propafenone also showed a lower incidence of side effects." | 6.66 | Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study. ( Ambrosioni, E; Bertaccini, P; Bracchetti, D; Cantelli, I; Naccarella, F; Palmieri, M, 1985) |
| "Propafenone is a considerably active drug against ventricular arrhythmias." | 6.65 | Antiarrhythmic effectiveness of propafenone compared to lorajmine in ventricular arrhythmias. Controlled clinical trial. ( Bianchini, C; Meoli, P; Rovelli, F; Sanna, G, 1983) |
| "Propafenone is a sodium channel blocking agent with a mild beta- and calcium channel-blocking activity." | 6.39 | Guidelines for the use of propafenone in treating supraventricular arrhythmias. ( Camm, AJ; Kishore, AG, 1995) |
| "Propafenone is a sodium channel blocking antiarrhythmic drug." | 6.39 | Propafenone: an effective agent for the management of supraventricular arrhythmias. ( Grant, AO, 1996) |
| "Propafenone is an orally active sodium channel blocking agent with beta-adrenoceptor antagonist and weak calcium antagonist activity." | 6.38 | Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. ( Bryson, HM; Fitton, A; Langtry, HD; Palmer, KJ, 1993) |
| "Drug management of ventricular arrhythmias follows few scientific principles." | 6.38 | Specific drugs for specific ventricular arrhythmias: an evaluation of current therapy and the role of propafenone. ( Campbell, RW; Murtazam, A, 1989) |
| "Propafenone is a Class I antiarrhythmic agent with weak beta-adrenoceptor antagonist activity which can be given both intravenously and orally." | 6.37 | Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. ( Brogden, RN; Harron, DW, 1987) |
| "Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias." | 6.17 | [Propafenone and flecainide in the therapy of ventricular arrhythmias]. ( Davini, A; Lattanzi, F; Paci, A; Paperini, L; Reisenhofer, B; Squarcini, G; Topi, A; Topi, PL, 1995) |
| "This study was designed to assess adverse effects of oral propafenone in a large number of pediatric patients." | 5.30 | Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. ( Janousek, J; Paul, T, 1998) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 5.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "5OHP suppressed reperfusion arrhythmias similar to the parent drug in a concentration-dependent manner." | 5.28 | The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model. ( Follath, F; Ha, HR; Oti-Amoako, K; Vozeh, S, 1990) |
| "In aconitine induced arrhythmias in rats, LG 6-101 and LG 6-102 did not differ in their antiarrhythmic effects from propafenone, whereas the protection against cardiac arrest was significantly (p less than or equal to 0." | 5.28 | Antiarrhythmic effects of two new propafenone related drugs. A study on four animal models of arrhythmia. ( Dittrich, P; Kukovetz, WR; Wascher, TC, 1991) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "Twelve patients with ventricular arrhythmias were given 300-900 mg oral of propafenon daily." | 5.27 | [Propafenone in refractory supraventricular arrhythmias]. ( Biagi, G; Casini, M; Lanzetta, T; Palumbo, E; Spargi, T; Svetoni, N, 1984) |
| "Auricular arrhythmia was observed in 41 patients with the following results: 16 successes among the 24 patients with paroxysmal fibrillation of flutter, 3 successes among the 8 patients with an arrhythmia reduced by cardioversion, and 3 successes among the 9 patients with auricular tachycardia, including 6 systolic tachycardias." | 5.27 | [Oral propafenone in refractory arrhythmia. Apropos of 68 patients]. ( Blanchot, P; Goldrach, S; Haissaguerre, M; Le Metayer, P; Regaudie, JJ; Vrancea, F; Warin, JF; Wicker, F, 1986) |
| "Propafenone is an effective well tolerated antiarrhythmic drug without major side effects in pediatric patients." | 5.27 | [The treatment of arrhythmias in infants and children using propafenone]. ( Dressler, F; Grävinghoff, L; Grütte, E; Jüngst, BK; Liersch, R; Nomayo, H; Puls, I; Rautenburg, HW; Schmaltz, A; Schumacher, G, 1985) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 5.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 5.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "In a selected group of 86 patients (60 males, 26 females) with symptomatic ventricular arrhythmias, possible interactions between metabolic and chiral effects at steady-state were investigated by comparing the plasma levels of propafenone, its major metabolites and the 2 structural isomers." | 5.07 | Steady-state plasma concentrations of propafenone--chirality and metabolism. ( Mitrovic, V; Schlepper, M; Volz, M, 1994) |
| "0 years) with hyperkinetic ventricular arrhythmias were treated for 30 days with 150 mg propafenone three times daily; the daily dosage was raised to 900 mg in non responders (< 85% reduction of ectopic ventricular beats/h)." | 5.07 | [Evaluation of the anti-arrhythmic action of propafenone treatment and its influence on left ventricular function]. ( Bonaiuto, M; Cinquegrani, M; Fodale, P; Giordano, G; Mileto, A; Oriti, S; Saitta, A; Saitta, M; Squadrito, F, 1993) |
| "Multivariate regression analysis of spontaneous arrhythmia variability and of different clinical variables to determine the short and long-term efficacy and safety of propafenone." | 5.07 | Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. ( Furtwängler, A; Geibel, A; Hohnloser, S; Just, H; Meinertz, T; Olschewski, M; Zehender, M, 1992) |
| "A double-blind, placebo-controlled trial comparing the antiarrhythmic effects of lidocaine (given intravenously as a bolus injection of 100 mg followed by an infusion of 2 mg min-1) and propafenone (given as a bolus of 105 mg followed by 300 mg orally every 8 h) was conducted in the first 24 h following acute myocardial infarction." | 5.06 | A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction. ( Atallah, G; Ferry, S; Kirkorian, G; Marchand, A; Mathieu, MP; Moleur, P; Stahl, C; Touboul, P; Vrancea, F; Zoheir, F, 1988) |
| "A placebo-controlled single-blind study was performed to evaluate the efficacy of oral propafenone on stable potentially malignant ventricular tachyarrhythmias in 13 patients who had suffered a myocardial infarction two months or longer before the trial." | 5.06 | [Efficacy of propafenone in the treatment of ventricular hyperkinetic arrhythmias in subjects with a history of myocardial infarction]. ( Carratino, L; De Caro, E; Ferroni, A; Vecchio, C; Zoni Berisso, M, 1987) |
| "We studied the efficacy of propafenone in 16 patients (pts) with exercise-induced ventricular arrhythmias (VA)." | 5.06 | The efficacy of propafenone on exercise-induced ventricular arrhythmias. ( Argyrakis, S; Cokkinos, DV; Hatzisavvas, J; Papantonakos, A; Perrakis, C, 1987) |
| "A placebo-controlled, randomized, double-blind, crossover study was performed in 14 patients with chronic, resistant, ventricular arrhythmias in order to evaluate the efficacy and safety of two new antiarrhythmic agents, propafenone and aprindine." | 5.05 | [Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo]. ( Amici, R; Ciampani, N; Costantini, C; Mocchegiani, R; Pigini, G; Purcaro, A, 1983) |
| "Propafenone, a new antiarrhythmic agent, was utilized in 30 patients with diverse heart disease who presented with sustained hemodynamically unstable ventricular arrhythmia." | 5.05 | Propafenone: a new agent for ventricular arrhythmia. ( Lown, B; Podrid, PJ, 1984) |
| "Propafenone, a new class I antiarrhythmic drug, given as a bolus injection followed by oral medication, or lidocaine were given to 20 consecutive patients admitted with chest pain suggesting acute myocardial infarction and showing high grades, i." | 5.05 | Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction. ( Ericsson, CG; Eriksson, S; Olsson, G; Rehnqvist, N; Svensson, G, 1984) |
| "In 15 patients with ventricular arrhythmias without previous treatment the effectiveness of 2-amino-2',6'-dimethylpropionanilide (tocainide, Xylotocan) and propafenone was compared in a cross-over-trial." | 5.05 | [Comparative studies of tocainide and propafenone in the treatment of ventricular arrhythmias]. ( Gebhardt, A; Hilpert, P; Schmuderer, R, 1984) |
| "The efficacy of propafenone hydrochloride, a new antiarrhythmic agent, was evaluated in the treatment of chronic stable ventricular arrhythmias." | 5.05 | Oral propafenone in the suppression of chronic stable ventricular arrhythmias. ( Kawalsky, DL; Myburgh, DP; Pincus, DR; Schamroth, CL; Schamroth, L; Scholtz, ME, 1985) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 4.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias." | 4.79 | Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. ( Boriani, G; Capucci, A, 1995) |
| "In children, supraventricular tachycardia is the most common form of arrhythmia, and propafenone is an effective class Ic antiarrhythmic agent used in this population." | 4.12 | Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia. ( Hsieh, YT; Huang, CF; Lin, CH; Lin, SC; Lin, YS; Liu, LY; Shen, LJ, 2022) |
| "This retrospective case series study sought to describe the safety and clinical effectiveness of propafenone for the control of arrhythmias in children with and without CHD or cardiomyopathy." | 4.12 | Electrophysiological effects and clinical utility of propafenone in children. ( Ferns, SJ; Gehi, AK; Hudak, ML; McKenzie, K; Singh, M, 2022) |
| " The purpose of this study was to assess the efficacy of the AADs disopyramide, quinidine, and propafenone on human atrial arrhythmias mediated by Pitx2-induced remodelling, from a single cell to the tissue level, using drug binding models with multi-channel pharmacology." | 4.02 | In Silico Assessment of Class I Antiarrhythmic Drug Effects on ( Bai, J; Gao, M; Lo, A; Lu, Y; Zhang, H; Zhao, J; Zhu, Y, 2021) |
| "We present two cases of proarrhythmia after propafenone treatment." | 3.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| " In 11 dogs the effects of myocardial ischemia, premature epicardial stimulation (PES) and propafenone on anisotropic conduction properties were tested using three-dimensional mapping techniques." | 3.72 | Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts. ( Bauer, A; Becker, R; Kraft, P; Kuebler, W; Schoels, W; Schreiner, KD; Senges, JC; Voss, F, 2003) |
| "To study the influence of propafenone associated with propofol on myocardial contractility (dP/dt and heart rate), coronary flow, and the incidence of arrhythmia in isolated rat hearts." | 3.72 | Effects of propafenone associated with propofol on myocardial contractility, heart rate, coronary flow, and the incidence of arrhythmia in isolated hearts of rats. ( Assis, NL; do Valle, GG; Garcia, SL; Gomes, OM, 2004) |
| " In view of recent atrial fibrillation with inadequate heart rate control, digoxin and propafenone were included in the therapeutic regimen." | 3.71 | [Proarrhythmic effects of propafenone in a woman with hepatopathy: is it always a simple drug in clinical practice?]. ( Brieda, M; Burelli, C; Cassin, M; Dametto, E; Hrovatin, E; Nicolosi, GL; Piazza, R; Zardo, F, 2002) |
| "To determine the effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia." | 3.71 | Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia. ( Cai, WM; Chen, B; Huang, YZ; Xu, J; Zhang, FM; Zhang, YD, 2002) |
| "The objective of the submitted work was to assess, using programmed stimulation of the cardiac ventricles during antiarrhythmic treatment (amiodarone and propafenon administered orally), the presence of indicators suggesting imminent ventricular ectopic proarrhythmia." | 3.69 | [Importance of programmed ventricular stimulation in the evaluation of proarrhythmic effects of orally administered anti-arrhythmia agents]. ( Parízek, P; Pidrman, V; Pleskot, M; Tilser, P, 1995) |
| "The effect of long-term treatment with propafenone, metoprolol and amiodarone was studied on the activity of Na,K-adenosine triphosphatase in lymphocytes and the plasma level of cAMP in patients with ventricular arrhythmias." | 3.69 | [The effect of treatment with propafenone, metoprolol and amiodarone on lymphocyte sodium efflux and level of cAMP in serum]. ( Kosmala, W, 1995) |
| "Tiracizine a new antiarrhythmic drug class Ia was tested in a open crossover study in a group of 46 patients with more than 2500 ventricular extrasystoles per 24 hours or with ventricular arrhythmias III or a higher Lown class." | 3.68 | [Tiracizine in the treatment of ventricular arrhythmia (preliminary study)]. ( Bytesník, J; Groch, L; Krausová, R; Stejfa, M; Zeman, K, 1993) |
| "The electrophysiological effects of combination therapy of mexiletine and propafenone were assessed using standard 12-lead electrocardiogram (standard ECG), signal-averaged ECG (SAECG), and ambulatory ECG in 31 patients with ventricular arrhythmias." | 3.68 | Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy. ( Haruna, M; Kato, H; Lee, S; Machii, T; Nonokawa, M; Takanaka, C; Yabe, S, 1992) |
| "One hundred and fourteen patients were included in an open multicenter trial of the prevention of atrial arrhythmias by propafenone and of the tolerability of this anti-arrhythmic agent after a year." | 3.68 | [Efficacy and tolerance of propafenone in the prevention after a year of recurrent atrial arrhythmia. Results of a multicenter study of 114 patients]. ( Maarek-Charbit, M; Motté, G; Sirinelli, A, 1992) |
| " Both, LG 6-101 and LG 6-102 showed strong antiarrhythmic effects against arrhythmias induced on the fifth day by infusion of aconitine (10 micrograms kg-1 min-1)." | 3.68 | LG 6-101 and LG 6-102, two new propafenone-related antiarrhythmic agents with good oral activity in rats. ( Dittrich, P; Kukovetz, WR; Wascher, TC, 1992) |
| "105 sequential patients with ventricular arrhythmias in a basal ECG-H recording, that were evaluated within 1 year with a new recording on amiodarone or propafenone, without major clinical events or therapeutic changes between the two recordings." | 3.68 | [Amiodarone and propafenone: evaluation using serial Holter recordings in patients with ventricular arrhythmia]. ( Adragão, P; Bonhorst, D; Seabra-Gomes, R; Ventosa, A, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 3.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone." | 3.67 | Propafenone for the treatment of severe ventricular arrhythmias. ( Bar-Shlomo, B; Boroomand-Rashti, K; Rabkin, SW; Rotem, CE, 1984) |
| "6 mg/min for 4-40 hrs), Propafenone (1-2 mg/Kg in 5 min + continuous infusion of 10-15 mcg/Kg/min for 24 hrs) and Mexiletine (250 mg in 15 min + 250 mg in 1 hr) have been evaluated in patients with acute myocardial infarction complicated by sinus tachycardia and hyperdynamic pattern, ventricular or supraventricular arrhythmias." | 3.67 | Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction. ( Ambrosini, F; Finzi, A; Lo Masto, M; Lotto, A; Massari, FM; Pagnoni, F; Valentini, R, 1984) |
| "The electrophysiological effects of lidocaine (L) and propafenone (P) in chronic myocardial infarction in relation to tissue drug concentrations (TDC) are unknown." | 3.67 | Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations. ( Agarwal, JB; Bracchetti, D; Helfant, RH; Naccarella, FF; Weintraub, WS, 1984) |
| "Propafenone disposition kinetics were studied after intravenous and oral doses in patients with ventricular arrhythmias." | 3.67 | Propafenone disposition kinetics in cardiac arrhythmia. ( Connolly, S; Harrison, DC; Kates, RE; Lebsack, C; Winkle, RA, 1984) |
| "Antiarrhythmic effects of three new drugs, propafenone, tocainide, and SUN 1165, were examined using three canine ventricular arrhythmia models, i." | 3.67 | Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. ( Hashimoto, K; Ishii, M; Komori, S; Mitsuhashi, H, 1985) |
| "The antiarrhythmic efficacy of Propafenone (PF) was evaluated in 24 patients with ventricular hyperkinetic arrhythmias by means of 24-hour Holter monitoring." | 3.67 | [Propafenone in ventricular hyperkinetic arrhythmias. Dynamic ECG evaluation of the acute oral test and short-term treatment]. ( Cappiello, E; Garimoldi, M; Pirastu, A; Sala, R; Sghirinzetti, M; Terranova, P, 1986) |
| "The purpose of our study was to evaluate the therapeutic and preventive action of propafenone on ventricular hyperkinetic arrhythmias (VHAs)." | 3.67 | [Medium term study of the efficacy of propafenone in the treatment of hyperkinetic ventricular arrhythmia]. ( Cairo, GF; Mascelli, G; Zangara, A; Zanni, PP, 1989) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 3.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "Thirty children aged from 3 months to 20 years were treated with propafenone 250 to 650 mg/m2 divided into 2 to 4 daily doses, for a mean period of 14 months (range: 4 days to 5 years); 8 had chronic atrial tachycardia, 9 had junctional arrhythmia and 13 had ventricular arrhythmia." | 3.67 | [Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases]. ( Batisse, A; Coumel, P; Do Ngoc, D; Fidelle, J; Loth, P; Lucet, V; Sidi, D; Villain, E; Vrancea, F, 1987) |
| " The antiarrhythmic potency of propafenone was evaluated in the guinea-pig isolated heart; arrhythmias were induced with (a) digitalis intoxication and (b) hypoxia followed by reoxygenation." | 3.67 | Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine. ( Amerini, S; Bernabei, R; Carbonin, P; Cerbai, E; Mugelli, A; Pahor, M, 1988) |
| "Thirty-two men with chronic ventricular arrhythmias responded to propafenone, a new potent antiarrhythmic agent, in short-term trials with 85% or greater reduction of total ventricular premature complexes (VPCs) per hour, 95% or greater reduction of ventricular couplets (VCs) per hour, and 100% abolition of ventricular tachycardia (VT) beats per 24 hours." | 3.67 | Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience. ( Baker, BJ; de Soyza, N; Dinh, H; Murphy, ML, 1988) |
| " route proved to be more potent and longer-acting than disopyramide, propaphenone and mexiletine against supraventricular and ventricular arrhythmias induced by chloroform, aconitine, ouabain and halothane-adrenaline." | 3.67 | Antiarrhythmic effects of a novel diamine derivative, AN-132, on several animal models of cardiac arrhythmias. ( Sakai, K; Takagi, M; Yamazaki, T, 1987) |
| "The efficacy of Propafenone to prevent exercise-induced ventricular arrhythmias (EIVA) has been studied in eleven patients affected by ischemic heart disease." | 3.67 | [Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy]. ( Arrigo, F; Giannetto, M; Luzza, F; Oreto, G; Patané, S; Virga, T, 1987) |
| "The hemodynamic and electrophysiologic effect of a combined intravenous infusion of lidocaine (100 mg bolus followed by 2 mg/min infusion) and propafenone (1 or 2 mg/kg) in patients with a history of ventricular arrhythmia was studied." | 3.67 | Hemodynamic and electrophysiologic effects of combined infusion of lidocaine and propafenone in humans. ( Feld, GK; Kirsten, E; Nademanee, K; Singh, BN, 1987) |
| "The relationship between debrisoquine metabolic phenotype and the pharmacokinetics and pharmacodynamics of propafenone was studied in 28 patients with chronic ventricular arrhythmias (22 extensive metabolizers [EMs] and six poor metabolizers [PMs] of debrisoquine)." | 3.67 | Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ( McAllister, CB; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Wilkinson, GR; Woosley, RL, 1987) |
| "During treatment with the class Ic antiarrhythmic agent propafenone, the drug appeared to cause malignant ventricular tachyarrhythmias in five patients." | 3.67 | Malignant ventricular tachyarrhythmias in association with propafenone treatment. ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "The effects of the antiarrhythmic drugs disopyramide (D), mexiletine (M), and propafenone (P) on left ventricular function after intravenous injection and after oral therapy of at least 48 hours, and of the combined oral application of D and M, were studied by M-mode echocardiography in patients with ventricular arrhythmias in whom antiarrhythmic therapy was indicated." | 3.66 | [The effect of disopyramide, mexiletine and propafenon after intravenous and oral administration on left ventricular function in the M-mode echocardiogram]. ( Böcker, K; Köhler, E; Loogen, F; Seipel, L, 1982) |
| "Diprafenone is a new antiarrhythmic agent with a dominant local anesthetic action and additional beta-sympathicolytic activity." | 2.66 | [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone]. ( Geibel, A; Hohnloser, S; Just, H; Landsrath, C; Meinertz, T; Zehender, M, 1988) |
| "Propafenone is a new class Ic antiarrhythmic compound with a broad pharmacologic profile." | 2.66 | Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose-ranging study. ( Guerrero, J; Kaplinsky, E; Kirsten, E; Singh, BN, 1988) |
| "cent) arrhythmia, in order to study its efficacy and tolerance." | 2.66 | [Efficacy and tolerance of propafenone in the treatment of cardiac rhythm disorders. Evaluation of a multicenter open trial on 3,687 patients]. ( Clémenty, J; Coste, P; Metzinger, M, 1987) |
| "Propafenone also showed a lower incidence of side effects." | 2.66 | Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study. ( Ambrosioni, E; Bertaccini, P; Bracchetti, D; Cantelli, I; Naccarella, F; Palmieri, M, 1985) |
| " With the intravenous administration of the drug in a dosage of 1." | 2.65 | [Propafenon therapy of arrhythmias in infancy and childhood (author's transl)]. ( Eigster, G; Weber, H; Wesselhoeft, H, 1981) |
| "Propafenone is a considerably active drug against ventricular arrhythmias." | 2.65 | Antiarrhythmic effectiveness of propafenone compared to lorajmine in ventricular arrhythmias. Controlled clinical trial. ( Bianchini, C; Meoli, P; Rovelli, F; Sanna, G, 1983) |
| "Propafenone was also effective in controlling couplets and nonsustained ventricular tachycardia." | 2.65 | Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity. ( Granrud, G; Hodges, M; Salerno, D, 1984) |
| "However, in some cases the presence of ventricular ectopic beats indicates susceptibility towards life-threatening arrhythmias or ventricular dysfunction." | 2.46 | [When and how to treat ventricular ectopic beats]. ( D'Este, D; Sorbo, MD, 2010) |
| "Propafenone is a sodium channel blocking agent with a mild beta- and calcium channel-blocking activity." | 2.39 | Guidelines for the use of propafenone in treating supraventricular arrhythmias. ( Camm, AJ; Kishore, AG, 1995) |
| "For some arrhythmias, such as atrial fibrillation, it seems likely that drug therapy will remain an important part of treatment." | 2.39 | Is there a need for new antiarrhythmic drugs? ( Roden, DM, 1996) |
| "Propafenone is a sodium channel blocking antiarrhythmic drug." | 2.39 | Propafenone: an effective agent for the management of supraventricular arrhythmias. ( Grant, AO, 1996) |
| "Propafenone is an orally active sodium channel blocking agent with beta-adrenoceptor antagonist and weak calcium antagonist activity." | 2.38 | Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. ( Bryson, HM; Fitton, A; Langtry, HD; Palmer, KJ, 1993) |
| "Drug management of ventricular arrhythmias follows few scientific principles." | 2.38 | Specific drugs for specific ventricular arrhythmias: an evaluation of current therapy and the role of propafenone. ( Campbell, RW; Murtazam, A, 1989) |
| " Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level." | 2.37 | Antiarrhythmic drug therapy. Recent advances and current status. ( Somberg, J, 1985) |
| "Propafenone is a Class I antiarrhythmic agent with weak beta-adrenoceptor antagonist activity which can be given both intravenously and orally." | 2.37 | Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. ( Brogden, RN; Harron, DW, 1987) |
| "Propafenone is an uncommonly encountered class IC antidysrhythmic that is a look-alike for the opioid, oxycodone/acetaminophen 5/325." | 1.37 | Overdose of propafenone surreptitiously sold as "Percocet". ( Curtis, JA; D'Orazio, JL, 2011) |
| "Maximum occurence of arrhythmias was observed 2." | 1.32 | Acute toxicity of propafenone in a case of suicidal attempt. ( Markovic, P; Petrikova, V; Rajnic, A; Stancak, B, 2004) |
| "This study was designed to assess adverse effects of oral propafenone in a large number of pediatric patients." | 1.30 | Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. ( Janousek, J; Paul, T, 1998) |
| "Propafenone promotes slow monomorphic VT, probably by use-dependent conduction slowing and wavelength shortening." | 1.30 | Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. ( Fabritz, CL; Franz, MR; Kirchhof, PF, 1998) |
| "Propafenone is a class Ic antiarrhythmic agent which also exhibits beta-adrenergic and fast sodium channel blockade." | 1.30 | Recurrent convulsions and cardiac conduction disturbances after propafenone overdose. ( Buffet, M; Grossenbacher, F; Lamiable, D; Rambourg-Schepens, MO, 1999) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 1.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| " During dosing (10 mg kg-1 twice a day for 10 days) no effects on the electrocardiogram, monitored in conscious animals, were observed despite modest reductions (15-18%) in the maximum rate of depolarization of papillary muscle excised 1 or 6 h after completion of the dosing regime." | 1.28 | Antiarrhythmic, electrophysiological and haemodynamic effects of prolonged oral dosing with Org 7797 in the anaesthetized rat. ( Delbressine, L; Harris, N; Kane, KA; Muir, AW; Winslow, E, 1992) |
| " Threshold was tested at baseline and at each dosage after 7 days of therapy." | 1.28 | Effects of oral propafenone therapy on chronic myocardial pacing threshold. ( Altamura, G; Bianconi, L; Boccadamo, R; Carpino, A; Iesi, AP; Serdoz, R; Toscano, S, 1992) |
| "A debrisoquine test was performed in 10." | 1.28 | Identification of propafenone metaboliser phenotype from plasma and urine excretion data. ( Belloni, M; Bernasconi, R; Cappiello, E; Castel, JM; Giani, P; Landolina, M; Latini, R; Leopaldi, D, 1992) |
| "5OHP suppressed reperfusion arrhythmias similar to the parent drug in a concentration-dependent manner." | 1.28 | The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model. ( Follath, F; Ha, HR; Oti-Amoako, K; Vozeh, S, 1990) |
| "Propafenone 2 mg/kg was injected intravenously in 21 dogs." | 1.28 | [Correlation of signal-averaged electrocardiograms with the threatening ventricular arrhythmia during recovery period of experimental acute myocardial infarction]. ( Zha, Y, 1991) |
| "Propafenone was administered to 58 patients with a mean age of 3." | 1.28 | Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. ( Kallfelz, HC; Paul, T; Reimer, A, 1991) |
| "The aim of this study was to evaluate plasma concentrations of propafenone (P) and 5-hydroxy-propafenone (5-OH-P) at steady state in 36 patients with ventricular premature beats, Lown class greater than or equal to 2, submitted to antiarrhythmic treatment with propafenone either in acute administration (AA) (300-450 mg) or in chronic administration (CA) (150-300 mg t." | 1.28 | [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone]. ( Ambrosioni, E; Baroni, M; Boriani, G; Capucci, A; Frabetti, L; Magnani, B; Marchesini, B; Strocchi, E, 1991) |
| "In aconitine induced arrhythmias in rats, LG 6-101 and LG 6-102 did not differ in their antiarrhythmic effects from propafenone, whereas the protection against cardiac arrest was significantly (p less than or equal to 0." | 1.28 | Antiarrhythmic effects of two new propafenone related drugs. A study on four animal models of arrhythmia. ( Dittrich, P; Kukovetz, WR; Wascher, TC, 1991) |
| "The arrhythmias were effectively controlled in 32 patients, but in another 32 patients propafenone therapy was ineffective; in six patients the evaluation was unclear." | 1.28 | Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy. ( Frey, B; Plass, H; Probst, P; Pürerfellner, H; Schmidinger, H; Steurer, G; Weber, H, 1991) |
| "Propafenone terminated tachyarrhythmias in all patients during or within a few minutes after stopping infusion (mean conversion time: 6." | 1.28 | [Use of propafenone in emergency therapy]. ( Di Ieso, N; Guardascione, A; Liguori, A; Pellegrino, G; Piatto, A; Ruggiero, P; Scarnera, P, 1989) |
| "Propafenone is an antiarrhythmic drug that produces a variable degree of beta-blockade in humans and is administered as a racemate." | 1.28 | Stereoselective disposition and pharmacologic activity of propafenone enantiomers. ( Eichelbaum, M; Funck-Brentano, C; Kroemer, HK; Roden, DM; Silberstein, DJ; Wood, AJ; Woosley, RL, 1989) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "The study covered the whole spectrum of cardiac arrhythmias (32 supraventricular, 41 ventricular), and their relation to the autonomic nervous system." | 1.27 | [Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases]. ( Assayag, P; Cauchemez, B; Coumel, P; Leclercq, JF; Maisonblanche, P, 1984) |
| "A worsening of arrhythmias was observed in 4/101 (3." | 1.27 | Worsening of arrhythmias during pharmacological treatment. ( Bettini, R; Dal Forno, P; Disertori, M; Furlanello, F; Gramegna, L; Inama, G; Vergara, G, 1984) |
| "Twelve patients with ventricular arrhythmias were given 300-900 mg oral of propafenon daily." | 1.27 | [Propafenone in refractory supraventricular arrhythmias]. ( Biagi, G; Casini, M; Lanzetta, T; Palumbo, E; Spargi, T; Svetoni, N, 1984) |
| "Emergency treatment of cardiac arrhythmias was required in 41 newborn and infants aged two days to 9 months (mean 77 days) from July 1977 until September 1981." | 1.27 | [Emergency treatment of arrhythmias in neonates and infants]. ( Eigster, G; Weber, H; Wesselhoeft, H, 1983) |
| "Propafenone has significantly improved our ability to control postoperative JET." | 1.27 | Newer antiarrhythmic drugs in children. ( Garson, A; Moak, JP; Smith, RT, 1987) |
| "We correlated the induction of these arrhythmias with the values of refractory period, conduction velocity, and wavelength during control and during administration of several drugs." | 1.27 | Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. ( Allessie, MA; Bonke, FI; Lammers, WJ; Rensma, PL; Schalij, MJ, 1988) |
| "Diprafenone is a new antiarrhythmic drug with a dominant local anaesthetic action and an additional beta-sympathicolytic activity." | 1.27 | [Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy]. ( Behrenbeck, T; Frenking, B; Gülker, H; Hasfeld, M; Heuer, H, 1987) |
| "Diprafenone (D) is a new class I c antiarrhythmic agent, structurally similar to propafenone." | 1.27 | Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction. ( Bender, F; Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| "Auricular arrhythmia was observed in 41 patients with the following results: 16 successes among the 24 patients with paroxysmal fibrillation of flutter, 3 successes among the 8 patients with an arrhythmia reduced by cardioversion, and 3 successes among the 9 patients with auricular tachycardia, including 6 systolic tachycardias." | 1.27 | [Oral propafenone in refractory arrhythmia. Apropos of 68 patients]. ( Blanchot, P; Goldrach, S; Haissaguerre, M; Le Metayer, P; Regaudie, JJ; Vrancea, F; Warin, JF; Wicker, F, 1986) |
| " Thus, in patients with refractory complex ventricular ectopic beats, propafenone was effective and well tolerated initially in 67% of patients and during long-term administration in 49%, and toxicity was minor in most patients." | 1.27 | Propafenone for the treatment of refractory complex ventricular ectopic activity. ( Gersh, BJ; Hammill, SC; Holmes, DR; Osborn, MJ; Sorenson, PB; Sugrue, DD; Wood, DL, 1986) |
| "Propafenone is an effective well tolerated antiarrhythmic drug without major side effects in pediatric patients." | 1.27 | [The treatment of arrhythmias in infants and children using propafenone]. ( Dressler, F; Grävinghoff, L; Grütte, E; Jüngst, BK; Liersch, R; Nomayo, H; Puls, I; Rautenburg, HW; Schmaltz, A; Schumacher, G, 1985) |
| "In the MVP group, the following arrhythmias were induced: nonsustained polymorphic VT in 10, VF in three, and ventricular flutter in one." | 1.27 | The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias. ( Gang, ES; Hamer, A; Mandel, WJ; Oseran, DS; Peter, T; Rosenthal, ME, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 134 (57.51) | 18.7374 |
| 1990's | 70 (30.04) | 18.2507 |
| 2000's | 12 (5.15) | 29.6817 |
| 2010's | 12 (5.15) | 24.3611 |
| 2020's | 5 (2.15) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Jiang, D | 1 |
| Banh, R | 1 |
| Gamal El-Din, TM | 1 |
| Tonggu, L | 1 |
| Lenaeus, MJ | 1 |
| Pomès, R | 1 |
| Zheng, N | 1 |
| Catterall, WA | 1 |
| Bai, J | 1 |
| Zhu, Y | 1 |
| Lo, A | 1 |
| Gao, M | 1 |
| Lu, Y | 1 |
| Zhao, J | 1 |
| Zhang, H | 1 |
| Lin, YS | 1 |
| Lin, SC | 1 |
| Hsieh, YT | 1 |
| Liu, LY | 1 |
| Lin, CH | 1 |
| Shen, LJ | 1 |
| Huang, CF | 1 |
| Singh, M | 1 |
| McKenzie, K | 1 |
| Hudak, ML | 1 |
| Gehi, AK | 1 |
| Ferns, SJ | 1 |
| Kapustnick, Y | 1 |
| Lutsenko, R | 1 |
| Sуdorenko, A | 1 |
| Balik, M | 1 |
| Maly, M | 1 |
| Brozek, T | 1 |
| Brestovansky, P | 1 |
| Khoury, J | 1 |
| Azzam, ZS | 1 |
| Gómez, R | 1 |
| Caballero, R | 1 |
| Barana, A | 1 |
| Amorós, I | 1 |
| De Palm, SH | 1 |
| Matamoros, M | 1 |
| Núñez, M | 1 |
| Pérez-Hernández, M | 1 |
| Iriepa, I | 1 |
| Tamargo, J | 2 |
| Delpón, E | 1 |
| Savio-Galimberti, E | 1 |
| Knollmann, BC | 1 |
| Juárez Olguín, H | 1 |
| Flores Pérez, C | 1 |
| Ramírez Mendiola, B | 1 |
| Coria Jiménez, R | 1 |
| Sandoval Ramírez, E | 1 |
| Flores Pérez, J | 1 |
| Tsiperfal, A | 1 |
| Scheibly, K | 1 |
| Matsuda, K | 1 |
| Jastrzebski, M | 1 |
| D'Orazio, JL | 1 |
| Curtis, JA | 1 |
| Saz, EU | 1 |
| Ucar, SK | 1 |
| Ulger, Z | 1 |
| Ersel, M | 1 |
| Cevik, C | 1 |
| Karapinar, B | 1 |
| Dąbrowska, B | 1 |
| D'Este, D | 1 |
| Sorbo, MD | 1 |
| Jacob, J | 1 |
| Heard, K | 1 |
| Podzolkov, VI | 1 |
| Tarzimanova, AI | 1 |
| Avci, A | 1 |
| Yilmaz, A | 1 |
| Celik, M | 1 |
| Demir, K | 1 |
| Keles, F | 1 |
| Hrovatin, E | 1 |
| Piazza, R | 1 |
| Brieda, M | 1 |
| Dametto, E | 1 |
| Zardo, F | 1 |
| Burelli, C | 1 |
| Cassin, M | 1 |
| Nicolosi, GL | 1 |
| Cai, WM | 1 |
| Xu, J | 1 |
| Chen, B | 1 |
| Zhang, FM | 1 |
| Huang, YZ | 1 |
| Zhang, YD | 1 |
| Bauer, A | 1 |
| Becker, R | 1 |
| Voss, F | 1 |
| Senges, JC | 1 |
| Kraft, P | 1 |
| Schreiner, KD | 1 |
| Kuebler, W | 1 |
| Schoels, W | 1 |
| Assis, NL | 1 |
| Gomes, OM | 1 |
| Garcia, SL | 1 |
| do Valle, GG | 1 |
| Stancak, B | 1 |
| Markovic, P | 1 |
| Rajnic, A | 1 |
| Petrikova, V | 1 |
| Wakaumi, M | 1 |
| Tsuruoka, S | 1 |
| Sakamoto, K | 1 |
| Shiga, T | 1 |
| Fujimura, A | 1 |
| Incorvaia, C | 1 |
| Pravettoni, C | 1 |
| Riario-Sforza, GG | 1 |
| Darbar, D | 1 |
| Roden, DM | 6 |
| Sanna, GP | 1 |
| Leclercq, JF | 4 |
| Georgiopoulos, G | 1 |
| Halkidis, H | 1 |
| Attuel, P | 1 |
| Maisonblanche, P | 2 |
| Coumel, P | 5 |
| Weber, H | 3 |
| Eigster, G | 2 |
| Wesselhoeft, H | 2 |
| Lüderitz, B | 1 |
| Assayag, P | 2 |
| Ledda, F | 1 |
| Mantelli, L | 1 |
| Menozzi, C | 1 |
| Lolli, G | 1 |
| Gheller, G | 1 |
| Monducci, I | 1 |
| Vergoni, W | 1 |
| Cattabiani, ML | 1 |
| Manenti, E | 1 |
| Casali, G | 1 |
| Sanna, G | 1 |
| Meoli, P | 1 |
| Bianchini, C | 1 |
| Rovelli, F | 1 |
| Purcaro, A | 1 |
| Amici, R | 1 |
| Ciampani, N | 1 |
| Costantini, C | 1 |
| Mocchegiani, R | 1 |
| Pigini, G | 1 |
| Salerno, DM | 2 |
| Granrud, G | 2 |
| Sharkey, P | 1 |
| Asinger, R | 1 |
| Hodges, M | 2 |
| Podrid, PJ | 4 |
| Lown, B | 2 |
| de Soyza, N | 2 |
| Terry, L | 1 |
| Murphy, ML | 3 |
| Thompson, CH | 1 |
| Doherty, JE | 1 |
| Sakhaii, M | 1 |
| Dinh, H | 2 |
| Salerno, D | 1 |
| Rehnqvist, N | 1 |
| Ericsson, CG | 1 |
| Eriksson, S | 1 |
| Olsson, G | 1 |
| Svensson, G | 1 |
| Rizzon, P | 1 |
| De Toma, L | 1 |
| Mangini, SG | 1 |
| Scrutinio, D | 1 |
| Lagioia, R | 1 |
| De Nicolò, M | 1 |
| Gebhardt, A | 1 |
| Schmuderer, R | 1 |
| Hilpert, P | 1 |
| Cauchemez, B | 1 |
| Furlanello, F | 7 |
| Gramegna, L | 1 |
| Dal Forno, P | 5 |
| Vergara, G | 6 |
| Bettini, R | 2 |
| Inama, G | 5 |
| Disertori, M | 6 |
| Zipes, DP | 2 |
| Prystowsky, EN | 2 |
| Heger, JJ | 2 |
| Naccarella, F | 3 |
| Marchesini, A | 1 |
| Palmieri, M | 3 |
| Ambrosioni, E | 4 |
| Bracchetti, D | 4 |
| Zeiler, RH | 1 |
| Gough, WB | 1 |
| El-Sherif, N | 1 |
| Marzegalli, M | 1 |
| Bernasconi, M | 1 |
| Brambilla, G | 1 |
| Micheletti, T | 1 |
| Potenza, S | 1 |
| Regalia, F | 1 |
| Barbaresco, L | 1 |
| Bossi, M | 1 |
| Finzi, A | 3 |
| Ambrosini, F | 2 |
| Pagnoni, F | 2 |
| Massari, FM | 2 |
| Valentini, R | 2 |
| Lotto, A | 3 |
| Rizzo, A | 1 |
| Fiorilli, R | 1 |
| Lisanti, P | 1 |
| Palumbo, E | 2 |
| Svetoni, N | 2 |
| Casini, M | 2 |
| Spargi, T | 2 |
| Biagi, G | 2 |
| Lanzetta, T | 2 |
| Rabkin, SW | 2 |
| Rotem, CE | 2 |
| Boroomand-Rashti, K | 2 |
| Bar-Shlomo, B | 1 |
| Lo Masto, M | 1 |
| Naccarella, FF | 1 |
| Agarwal, JB | 1 |
| Weintraub, WS | 1 |
| Helfant, RH | 1 |
| Angermann, C | 1 |
| Jahrmärker, H | 1 |
| Guarnerio, M | 3 |
| Padrini, R | 1 |
| Gobbato, S | 1 |
| Ferrari, M | 1 |
| Fidelle, J | 2 |
| Connolly, S | 1 |
| Lebsack, C | 1 |
| Winkle, RA | 3 |
| Harrison, DC | 2 |
| Kates, RE | 5 |
| Connolly, SJ | 1 |
| Lebsack, CS | 1 |
| Botti, G | 1 |
| Bonatti, V | 1 |
| Rolli, A | 1 |
| Molinis, G | 2 |
| Valente, M | 2 |
| Tuniz, D | 2 |
| Maisano, G | 2 |
| Seipel, L | 2 |
| Breithardt, G | 2 |
| Stefenelli, C | 1 |
| Zuechi, S | 1 |
| Harapat, SR | 1 |
| Böcker, K | 1 |
| Köhler, E | 1 |
| Loogen, F | 1 |
| Ku, FS | 1 |
| del Corso, P | 1 |
| Lombardi, G | 1 |
| Rocha, PJ | 1 |
| Albuquerque, DC | 1 |
| Benchimol, CB | 1 |
| Albanesi Filho, FM | 1 |
| Magalhães, ME | 1 |
| Schlesinger, P | 1 |
| Benchimol, AB | 1 |
| Germiniani, H | 1 |
| Germiniani, Cde L | 1 |
| Pleskot, M | 1 |
| Pidrman, V | 1 |
| Tilser, P | 1 |
| Parízek, P | 1 |
| Heusch, A | 1 |
| Kramer, HH | 1 |
| Krogmann, ON | 1 |
| Rammos, S | 1 |
| Bourgeous, M | 1 |
| Ye, VZ | 1 |
| Wyse, KR | 1 |
| Campbell, TJ | 1 |
| Bryson, HM | 1 |
| Palmer, KJ | 1 |
| Langtry, HD | 1 |
| Fitton, A | 1 |
| Dodo, H | 1 |
| Gow, RM | 1 |
| Hamilton, RM | 1 |
| Freedom, RM | 2 |
| Capucci, A | 4 |
| Boriani, G | 3 |
| Volz, M | 1 |
| Mitrovic, V | 1 |
| Schlepper, M | 3 |
| Auricchio, A | 1 |
| Auricchio, U | 1 |
| Chiariello, L | 1 |
| Câmpeanu, A | 1 |
| Rădoi, M | 1 |
| Serban-Pârâu, G | 1 |
| Pleşca, O | 1 |
| Nuţă, M | 1 |
| Teodorescu, V | 1 |
| Titirigă, M | 1 |
| Bertoldi, A | 1 |
| Stejfa, M | 2 |
| Zeman, K | 1 |
| Groch, L | 1 |
| Bytesník, J | 1 |
| Krausová, R | 1 |
| Saitta, A | 1 |
| Bonaiuto, M | 1 |
| Mileto, A | 1 |
| Oriti, S | 1 |
| Cinquegrani, M | 1 |
| Giordano, G | 1 |
| Fodale, P | 1 |
| Saitta, M | 1 |
| Squadrito, F | 1 |
| Aupetit, JF | 2 |
| Timour, Q | 2 |
| Larbre, JP | 2 |
| Loufoua-Moundanga, J | 2 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 2 |
| Kishore, AG | 1 |
| Camm, AJ | 1 |
| Kosmala, W | 1 |
| Mondillo, S | 1 |
| Faglia, S | 1 |
| D'Aprile, N | 1 |
| Mangiacotti, L | 1 |
| Campolo, MA | 1 |
| Agricola, E | 1 |
| Palazzuoli, V | 1 |
| Chimienti, M | 1 |
| Cullen, MT | 1 |
| Casadei, G | 1 |
| Bianconi, L | 2 |
| Mennuni, M | 1 |
| Lukic, V | 1 |
| Castro, A | 1 |
| Chieffi, M | 1 |
| Santini, M | 1 |
| Grant, AO | 1 |
| Kroemer, HK | 4 |
| Botsch, S | 1 |
| Heinkele, G | 1 |
| Schick, M | 1 |
| Paperini, L | 1 |
| Davini, A | 1 |
| Lattanzi, F | 1 |
| Topi, A | 1 |
| Reisenhofer, B | 1 |
| Squarcini, G | 1 |
| Paci, A | 1 |
| Topi, PL | 1 |
| Lardoux, H | 1 |
| Maison Blanche, P | 1 |
| Marchand, X | 1 |
| Canler, A | 1 |
| Rouesnel, P | 2 |
| Bleinc, D | 1 |
| Péraudeau, P | 1 |
| Scheck, F | 1 |
| Tumová, I | 1 |
| Racanská, E | 1 |
| Csöllei, J | 1 |
| Ecker, G | 1 |
| Otrusník, R | 1 |
| Svec, P | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 1 |
| Wen, ZC | 1 |
| Tai, CT | 1 |
| Chiang, CE | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Janousek, J | 1 |
| Paul, T | 2 |
| Kirchhof, PF | 1 |
| Fabritz, CL | 1 |
| Franz, MR | 1 |
| Rae, AP | 1 |
| Villani, GQ | 1 |
| Piepoli, MF | 1 |
| Aschieri, D | 1 |
| Rambourg-Schepens, MO | 1 |
| Grossenbacher, F | 1 |
| Buffet, M | 1 |
| Lamiable, D | 1 |
| Pelter, MM | 1 |
| Adams, MG | 1 |
| Takanaka, C | 1 |
| Nonokawa, M | 1 |
| Machii, T | 1 |
| Lee, S | 1 |
| Kato, H | 1 |
| Haruna, M | 1 |
| Yabe, S | 1 |
| Sirinelli, A | 1 |
| Maarek-Charbit, M | 1 |
| Motté, G | 1 |
| Delbressine, L | 1 |
| Harris, N | 1 |
| Kane, KA | 1 |
| Muir, AW | 2 |
| Winslow, E | 2 |
| Boccadamo, R | 1 |
| Toscano, S | 1 |
| Serdoz, R | 1 |
| Carpino, A | 1 |
| Iesi, AP | 1 |
| Altamura, G | 1 |
| Todt, H | 1 |
| Krumpl, G | 1 |
| Krejcy, K | 1 |
| Raberger, G | 1 |
| Brakhmann, I | 1 |
| Shmitt, K | 1 |
| Baĭer, T | 1 |
| Valdeker, B | 1 |
| Khilbel, T | 1 |
| Kiubler, V | 1 |
| Rein, S | 1 |
| Karpov, RS | 1 |
| Gratsianskiĭ, NA | 1 |
| Vertkin, AL | 1 |
| Sidorenko, BA | 1 |
| Dobrotvorskaia, TE | 1 |
| Doshchitsin, VL | 1 |
| Shevchenko, OP | 1 |
| Gimrikh, EO | 1 |
| Poirier, JM | 1 |
| Joannides, R | 1 |
| Geffroy-Josse, S | 1 |
| Fillastre, JP | 1 |
| Etienne, I | 1 |
| Birgersdotter-Green, U | 1 |
| Latini, R | 4 |
| Belloni, M | 1 |
| Bernasconi, R | 1 |
| Cappiello, E | 2 |
| Giani, P | 2 |
| Landolina, M | 2 |
| Leopaldi, D | 1 |
| Castel, JM | 1 |
| Wascher, TC | 2 |
| Dittrich, P | 2 |
| Kukovetz, WR | 2 |
| Zehender, M | 3 |
| Hohnloser, S | 3 |
| Geibel, A | 3 |
| Furtwängler, A | 1 |
| Olschewski, M | 1 |
| Meinertz, T | 3 |
| Just, H | 3 |
| Vincenti, A | 1 |
| Cavalli, A | 1 |
| Gaita, F | 3 |
| Babuty, D | 1 |
| Cosnay, P | 1 |
| Bine-Scheck, F | 1 |
| Arnaud, R | 1 |
| Fauchier, JP | 1 |
| Oti-Amoako, K | 1 |
| Vozeh, S | 1 |
| Ha, HR | 1 |
| Follath, F | 1 |
| Ventosa, A | 1 |
| Adragão, P | 1 |
| Bonhorst, D | 1 |
| Seabra-Gomes, R | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Marshall, RJ | 1 |
| Zha, Y | 1 |
| Reimer, A | 1 |
| Kallfelz, HC | 1 |
| Zuanetti, G | 2 |
| Neilson, JM | 1 |
| Schwartz, PJ | 3 |
| Ewing, DJ | 1 |
| Vaughan Williams, EM | 1 |
| Gerentes-Chassagne, I | 1 |
| Guccione, P | 1 |
| Drago, F | 1 |
| Di Donato, RM | 1 |
| Cicini, MP | 1 |
| Pasquini, L | 1 |
| Marino, B | 1 |
| Marcelletti, C | 1 |
| Ragonese, P | 1 |
| Strocchi, E | 1 |
| Marchesini, B | 2 |
| Baroni, M | 1 |
| Frabetti, L | 2 |
| Magnani, B | 2 |
| Katz, MR | 1 |
| Hernandez, M | 1 |
| Reder, RF | 1 |
| Marinchak, RA | 1 |
| Rials, SJ | 1 |
| Kowey, PR | 1 |
| Healy, B | 1 |
| Steurer, G | 1 |
| Schmidinger, H | 1 |
| Plass, H | 1 |
| Frey, B | 1 |
| Pürerfellner, H | 1 |
| Probst, P | 1 |
| Sagie, A | 1 |
| Strasberg, B | 1 |
| Puech, P | 1 |
| Gagnol, JP | 1 |
| Rozsíval, V | 1 |
| Shen, EN | 1 |
| Spes, CH | 1 |
| Angermann, CE | 1 |
| Horn, K | 1 |
| Strasser, T | 1 |
| Mudra, H | 1 |
| Landgraf, R | 1 |
| Theisen, K | 1 |
| Zalzstein, E | 1 |
| Koren, G | 1 |
| Bryson, SM | 1 |
| Funck-Brentano, C | 3 |
| Lee, JT | 1 |
| Hashimoto, K | 1 |
| Ishii, M | 1 |
| Komori, S | 1 |
| Mitsuhashi, H | 1 |
| Garimoldi, M | 1 |
| Sghirinzetti, M | 1 |
| Pirastu, A | 1 |
| Sala, R | 1 |
| Terranova, P | 1 |
| Landsrath, C | 1 |
| Balducelli, M | 1 |
| Tomasi, L | 1 |
| Arranz Peña, MI | 1 |
| Moro, C | 1 |
| Liem, LB | 1 |
| Abi Samra, F | 1 |
| Cairo, GF | 1 |
| Zanni, PP | 1 |
| Mascelli, G | 1 |
| Zangara, A | 1 |
| Liguori, A | 1 |
| Pellegrino, G | 1 |
| Di Ieso, N | 1 |
| Piatto, A | 1 |
| Ruggiero, P | 1 |
| Scarnera, P | 1 |
| Guardascione, A | 1 |
| Petri, H | 1 |
| Kafka, W | 1 |
| Rudolph, W | 1 |
| Aguglia, F | 1 |
| Gnecchi, M | 1 |
| De Marzio, P | 1 |
| Grubb, BP | 1 |
| Murtazam, A | 1 |
| Campbell, RW | 1 |
| Vitak, J | 1 |
| Kunz-Fritze, A | 1 |
| Silberstein, DJ | 1 |
| Wood, AJ | 1 |
| Eichelbaum, M | 1 |
| Woosley, RL | 3 |
| Pavlou, H | 1 |
| Zoble, RG | 1 |
| Kirsten, EB | 1 |
| Brewington, J | 1 |
| Michel, D | 1 |
| Liusov, VA | 1 |
| Dudaev, VA | 1 |
| Borodkin, VV | 1 |
| Rudakov, AV | 1 |
| Bobbio, M | 1 |
| Vado, A | 1 |
| Uslenghi, E | 1 |
| Bocchiardo, M | 2 |
| Somberg, J | 1 |
| Cheriex, EC | 1 |
| Krijne, R | 1 |
| Brugada, P | 1 |
| Heymeriks, J | 1 |
| Wellens, HJ | 1 |
| Singh, BN | 2 |
| Kaplinsky, E | 1 |
| Kirsten, E | 2 |
| Guerrero, J | 1 |
| Huang, SK | 1 |
| Marcus, FI | 1 |
| Moak, JP | 1 |
| Smith, RT | 1 |
| Garson, A | 1 |
| Priori, SG | 1 |
| Bonazzi, O | 1 |
| Facchini, M | 1 |
| Varisco, T | 1 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Sidi, D | 1 |
| Batisse, A | 1 |
| Loth, P | 1 |
| Vrancea, F | 3 |
| Villain, E | 1 |
| Lanza, GA | 1 |
| Tamburi, S | 1 |
| Mondello Malvestiti, FM | 1 |
| Rebuzzi, AG | 1 |
| Lucente, M | 1 |
| Puddu, PE | 1 |
| Rouet, R | 1 |
| Brunozzi, LT | 1 |
| Meniconi, L | 1 |
| Chiocchi, P | 1 |
| Liberati, R | 1 |
| Madsen, JK | 1 |
| Nielsen, H | 1 |
| Madsen, BK | 1 |
| Amerini, S | 1 |
| Bernabei, R | 1 |
| Carbonin, P | 1 |
| Cerbai, E | 1 |
| Mugelli, A | 1 |
| Pahor, M | 1 |
| Touboul, P | 1 |
| Moleur, P | 1 |
| Mathieu, MP | 1 |
| Ferry, S | 1 |
| Kirkorian, G | 1 |
| Atallah, G | 1 |
| Marchand, A | 1 |
| Stahl, C | 1 |
| Zoheir, F | 1 |
| Somberg, JC | 1 |
| Tepper, D | 1 |
| Landau, S | 1 |
| Jonason, T | 1 |
| Ringqvist, I | 1 |
| Bandh, S | 1 |
| Nilsson, G | 1 |
| Nilsson, H | 1 |
| Lidell, C | 1 |
| Bjerle, P | 1 |
| Olofsson, BO | 1 |
| Clémenty, J | 1 |
| Coste, P | 1 |
| Metzinger, M | 1 |
| McKinnon, J | 1 |
| Zoni Berisso, M | 1 |
| Carratino, L | 1 |
| De Caro, E | 1 |
| Ferroni, A | 1 |
| Vecchio, C | 1 |
| Harron, DW | 1 |
| Brogden, RN | 1 |
| Baker, BJ | 2 |
| Rensma, PL | 1 |
| Allessie, MA | 1 |
| Lammers, WJ | 1 |
| Bonke, FI | 1 |
| Schalij, MJ | 1 |
| Bianchi, G | 1 |
| Manfredonia, A | 1 |
| Lepori, G | 1 |
| Locatelli, A | 1 |
| Di Salvo, F | 1 |
| De Jaegere, P | 1 |
| Huyghens, L | 1 |
| Dewilde, P | 1 |
| Spác, J | 1 |
| Vítovec, J | 1 |
| Havlát, F | 1 |
| Tomaszewski, A | 1 |
| Kleinrok, A | 1 |
| Markiewicz, M | 1 |
| Ranieri, L | 1 |
| D'Alonzo, S | 1 |
| Calvani, V | 1 |
| Antoncecchi, E | 2 |
| Sakai, K | 1 |
| Yamazaki, T | 1 |
| Takagi, M | 1 |
| Heuer, H | 1 |
| Gülker, H | 2 |
| Hasfeld, M | 1 |
| Frenking, B | 1 |
| Behrenbeck, T | 1 |
| Thale, J | 1 |
| Hindricks, G | 1 |
| Haverkamp, W | 1 |
| Bender, F | 1 |
| Cokkinos, DV | 1 |
| Perrakis, C | 1 |
| Argyrakis, S | 1 |
| Hatzisavvas, J | 1 |
| Papantonakos, A | 1 |
| Patané, S | 1 |
| Virga, T | 1 |
| Giannetto, M | 1 |
| Luzza, F | 1 |
| Oreto, G | 1 |
| Arrigo, F | 1 |
| Feld, GK | 1 |
| Nademanee, K | 1 |
| Haissaguerre, M | 1 |
| Wicker, F | 1 |
| Goldrach, S | 1 |
| Regaudie, JJ | 1 |
| Le Metayer, P | 1 |
| Warin, JF | 1 |
| Blanchot, P | 1 |
| Vanoli, E | 1 |
| Vázquez García, A | 1 |
| Marcos Sánchez, F | 1 |
| Górgolas Hernández-Mora, P | 1 |
| Durán Pérez-Navarro, A | 1 |
| Pepi, R | 1 |
| Rotatori, D | 1 |
| Mori, A | 1 |
| Nascimbeni, F | 1 |
| Vitale, P | 1 |
| De Stefano, R | 1 |
| Perna, B | 1 |
| Romano, A | 1 |
| Iacono, A | 1 |
| Richiardi, E | 1 |
| Asteggiano, R | 1 |
| Pinnavaia, A | 1 |
| Di Leo, M | 1 |
| Rosettani, E | 1 |
| Brusca, A | 1 |
| Santinelli, V | 1 |
| De Paola, M | 1 |
| Smimmo, D | 1 |
| Turco, P | 1 |
| Condorelli, M | 1 |
| Martelli, F | 1 |
| Budde, T | 1 |
| Beyer, M | 1 |
| Passlick, J | 1 |
| Grabensee, B | 1 |
| Siddoway, LA | 1 |
| Thompson, KA | 1 |
| McAllister, CB | 1 |
| Wang, T | 1 |
| Wilkinson, GR | 1 |
| Sánchez Domínguez, J | 1 |
| Roldán, I | 1 |
| Navarro, A | 1 |
| Villa, JG | 1 |
| Urbina, FJ | 1 |
| Barciela, R | 1 |
| Barras, C | 1 |
| Schamroth, L | 1 |
| Myburgh, DP | 1 |
| Schamroth, CL | 1 |
| Scholtz, ME | 1 |
| Pincus, DR | 1 |
| Kawalsky, DL | 1 |
| Cantelli, I | 1 |
| Bertaccini, P | 1 |
| Dinh, HA | 1 |
| deSoyza, N | 1 |
| Franciosa, JA | 1 |
| Kozák, P | 1 |
| Stárek, A | 1 |
| Hes, I | 1 |
| Spacek, R | 1 |
| Härtel, G | 1 |
| Tkaczewski, W | 1 |
| Goch, JH | 1 |
| Bała, T | 1 |
| Dziekański, S | 1 |
| Zheng, DS | 1 |
| Wang, BY | 1 |
| Graboys, TB | 1 |
| Lampert, S | 1 |
| Hammill, SC | 1 |
| Sorenson, PB | 1 |
| Wood, DL | 1 |
| Sugrue, DD | 1 |
| Osborn, MJ | 1 |
| Gersh, BJ | 1 |
| Holmes, DR | 1 |
| Alboni, P | 1 |
| Pirani, R | 1 |
| Paparella, N | 1 |
| Candini, GC | 1 |
| Tomasi, AM | 1 |
| Masoni, A | 1 |
| Yee, YG | 1 |
| Dressler, F | 1 |
| Grävinghoff, L | 1 |
| Grütte, E | 1 |
| Jüngst, BK | 1 |
| Liersch, R | 1 |
| Nomayo, H | 1 |
| Puls, I | 1 |
| Rautenburg, HW | 1 |
| Schmaltz, A | 1 |
| Schumacher, G | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Buss, J | 1 |
| Neuss, H | 1 |
| Bilgin, Y | 1 |
| Rosenthal, ME | 1 |
| Hamer, A | 1 |
| Gang, ES | 1 |
| Oseran, DS | 1 |
| Mandel, WJ | 1 |
| Peter, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
33 reviews available for propafenone and Arrhythmia
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
[When and how to treat ventricular ectopic beats].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Encainide; Exercise Test; Humans; | 2010 |
Pharmacogenetics of antiarrhythmic therapy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arylamine N-Acetyltransferase; ATP Binding Cassette Tr | 2006 |
[The use of propafenon in the acute and chronic treatment of supraventricular and ventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Female; Humans; Male; | 1983 |
Electrophysiology and pharmacology of aprindine, encainide, and propafenone.
Topics: Action Potentials; Anilides; Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Elect | 1984 |
Propafenone--a new antiarrhythmic drug.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Heart Conduction System; Hemodynami | 1980 |
[Progress in arrhythmology].
Topics: Adolescent; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atropine; Cardiac P | 1981 |
Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Cardiovascular System; Humans; Propafenone; Receptors, Adrenergic, be | 1993 |
Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Electrophysiology; Female; | 1995 |
[Role of propafenone in anti-arrhythmia treatment].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Drug Interactions; Electrophysiology; Humans; Propafenone | 1993 |
Guidelines for the use of propafenone in treating supraventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Surgical Procedure | 1995 |
Is there a need for new antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Propafeno | 1996 |
Propafenone: an effective agent for the management of supraventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Propafenone; Tachycardia, Supraventri | 1996 |
[Propafenone and flecainide in the therapy of ventricular arrhythmias].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Drug Evaluation; | 1995 |
Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Controlled Clinic | 1998 |
The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; | 1999 |
Propafenone for cardiac arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Drug Interactions; Electrocardiography; Hemodynamics; Humans; Propafe | 1992 |
Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiograph | 1991 |
Propafenone for malignant ventricular arrhythmia: an analysis of the literature.
Topics: Administration, Oral; Arrhythmias, Cardiac; Drug Evaluation; Heart Ventricles; Humans; Injections, I | 1991 |
[Class Ic antiarrhythmic drugs--flecainide and propafenone].
Topics: Arrhythmias, Cardiac; Flecainide; Humans; Propafenone | 1990 |
Class IC drugs: propafenone and flecainide.
Topics: Arrhythmias, Cardiac; Flecainide; Humans; Propafenone | 1990 |
Propafenone: a promising new antiarrhythmic agent.
Topics: Arrhythmias, Cardiac; Chemical Phenomena; Chemistry; Electrophysiology; Heart Conduction System; Hum | 1990 |
Propafenone.
Topics: Arrhythmias, Cardiac; Heart; Humans; Propafenone | 1990 |
Update: cardiac antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1989 |
The clinical use of class IC antiarrhythmic drugs.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Propafenone | 1989 |
Propafenone--a new agent for the treatment of ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Humans; Propafenone; Ventricular Fibrillation | 1989 |
Specific drugs for specific ventricular arrhythmias: an evaluation of current therapy and the role of propafenone.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Ventricles; Humans; Propafenone | 1989 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrh | 1985 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecaini | 1986 |
Propafenone: a new antiarrhythmic agent.
Topics: Arrhythmias, Cardiac; Humans; Propafenone | 1988 |
Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
Topics: Arrhythmias, Cardiac; Humans; Propafenone | 1987 |
Propafenone, a review of its profile.
Topics: Arrhythmias, Cardiac; Humans; Propafenone | 1987 |
Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1985 |
45 trials available for propafenone and Arrhythmia
| Article | Year |
|---|---|
[Propafenon therapy of arrhythmias in infancy and childhood (author's transl)].
Topics: Adolescent; Age Factors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Atrioventricu | 1981 |
Antiarrhythmic effectiveness of propafenone compared to lorajmine in ventricular arrhythmias. Controlled clinical trial.
Topics: Adolescent; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as | 1983 |
[Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo].
Topics: Adult; Aged; Aprindine; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Double-Blin | 1983 |
A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Me | 1984 |
Propafenone: a new agent for ventricular arrhythmia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Ech | 1984 |
Effect of propafenone in patients with stable ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Bundle-Branch Block; Clin | 1984 |
Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Digoxin; Double-Blind | 1984 |
Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Heart | 1984 |
Holter monitoring comparative assessment of propafenone and dihydroquinidine efficacy in the treatment of premature ventricular beats.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electroca | 1983 |
[Comparative studies of tocainide and propafenone in the treatment of ventricular arrhythmias].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; F | 1984 |
[Comparative evaluation of mexiletine and propafenone by dynamic electrocardiography].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; H | 1984 |
[Comparative studies on the cardiodepressant effect of disopyramide, mexiletine and propafenon].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Echocardiography; Female; Heart R | 1983 |
Clinical pharmacology of propafenone.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspartate Aminotransferases; Dose-Respons | 1983 |
Comparison of the efficacy of propafenone versus disopyramide for complex premature ventricular contractions. Evaluation with long-term monitoring.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Disopyramide | 1982 |
Steady-state plasma concentrations of propafenone--chirality and metabolism.
Topics: Adult; Aged; Arrhythmias, Cardiac; Delayed-Action Preparations; Double-Blind Method; Female; Humans; | 1994 |
Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone.
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Exercise Test; Female; Flecainide; Humans; Male; | 1994 |
[Evaluation of the anti-arrhythmic action of propafenone treatment and its influence on left ventricular function].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Evaluation; F | 1993 |
[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Drug Sy | 1995 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chron | 1996 |
[Propafenone and flecainide in the therapy of ventricular arrhythmias].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Drug Evaluation; | 1995 |
[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation | 1996 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms.
Topics: Adult; Age Factors; Aged; Arrhythmias, Cardiac; Coronary Disease; Drug Administration Schedule; Elec | 1992 |
Washout of long-term treatment with flecainide and propafenone in patients with complex ventricular arrhythmias and cardiac disease. Antiarrhythmic Drug Evaluation Group.
Topics: Arrhythmias, Cardiac; Electrocardiography; Flecainide; Heart Diseases; Humans; Male; Middle Aged; Pr | 1992 |
[Comparison of the efficacy/tolerability ratio of cibenzoline and propafenone in the treatment of ventricular arrhythmia].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Female; Humans; Imidazoles; Male; | 1992 |
Propafenone for cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Heart Ventricles; Humans; Propafenone; Tachycardia | 1990 |
[Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as | 1988 |
[Therapy of ventricular arrhythmias with propafenone].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiac Pac | 1985 |
Antiarrhythmic efficacy and tolerance of oral propafenone in patients with frequent ventricular arrhythmias: experience of a multicentre study.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Drug Administration Schedule; Electrocardio | 1989 |
Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Double-Blind | 1989 |
Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose-ranging study.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Clinical Trials as Topic; Dose-Response Relati | 1988 |
A comparative evaluation of the effects of propafenone and lidocaine on early ventricular arrhythmias after acute myocardial infarction.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Female; Heart Rupture, Post-Infar | 1988 |
Propafenone versus disopyramide for treatment of chronic symptomatic ventricular arrhythmias. A multicenter study.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Disopyramide; Electroc | 1988 |
[Efficacy and tolerance of propafenone in the treatment of cardiac rhythm disorders. Evaluation of a multicenter open trial on 3,687 patients].
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; | 1987 |
Comparison of propafenone and disopyramide in the treatment of ventricular premature complexes: a randomized double blind crossover placebo controlled trial.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Double-Blind Method; Gastrointestinal | 1987 |
[Efficacy of propafenone in the treatment of ventricular hyperkinetic arrhythmias in subjects with a history of myocardial infarction].
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; Female; Follow-Up Studies | 1987 |
[Clinical experience with the antiarrhythmic propafenone (Rytmonorm)].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Female; | 1986 |
The efficacy of propafenone on exercise-induced ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Electrocardiography; Female; Heart Rate; Heart Ve | 1987 |
Oral propafenone in the suppression of chronic stable ventricular arrhythmias.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; | 1985 |
Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: placebo-controlled, double-blind, randomized crossover study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; D | 1985 |
Efficacy of propafenone compared with quinidine in chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Hu | 1985 |
[Propafenone--a new antiarrhythmic agent. Clinical experience].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Propafenone; P | 1985 |
Efficacy of oral propafenone in chronic ventricular arrhythmias: a placebo controlled cross-over exercise study.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinical | 1985 |
[Propafenone in the treatment of arrhythmia].
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Prop | 1985 |
156 other studies available for propafenone and Arrhythmia
| Article | Year |
|---|---|
Open-state structure and pore gating mechanism of the cardiac sodium channel.
Topics: Animals; Arrhythmias, Cardiac; Cryoelectron Microscopy; Heart Rate; HEK293 Cells; Humans; Ion Channe | 2021 |
In Silico Assessment of Class I Antiarrhythmic Drug Effects on
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Computer Simulation; Dis | 2021 |
Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia.
Topics: Administration, Oral; Arrhythmias, Cardiac; Child; Drug Compounding; Drug Stability; Humans; Pharmac | 2022 |
Electrophysiological effects and clinical utility of propafenone in children.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child, Preschool; Coronary Disease; | 2022 |
COMBINED PHARMACOLOGICAL THERAPY INCLUDING SEVERAL ANTIARRHYTHMIC AGENTS FOR TREATMENT OF DIFFERENT DISORDERS OF CARDIAC RHYTHM.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Propafenone; Sotalol | 2021 |
Reply.
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Metoprolol; Propafenone; Shock, Septic | 2018 |
Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Metoprolol; Propafenone; Shock, Se | 2018 |
Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Binding Sites; CHO Cells; Cricetulus; Cystein | 2014 |
Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
Topics: Animals; Arrhythmias, Cardiac; Caffeine; Calcium; Calcium Signaling; Calsequestrin; Cell Membrane Pe | 2015 |
Extemporaneous suspension of propafenone: attending lack of pediatric formulations in Mexico.
Topics: Administration, Oral; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chemistry, | 2008 |
Can QRS Widening be a result of propafenone overdose?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Consciousness Disorders; Drug Ove | 2008 |
[Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bundle-Branch Blo | 2008 |
Overdose of propafenone surreptitiously sold as "Percocet".
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Labeling; Drug Overdose; Electrocardi | 2011 |
Successful treatment of suicidal mega dose of propafenone intoxication - a case report.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Propa | 2010 |
[Editorial].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Humans; Propafenone | 2010 |
Second case of the use of intravenous fat emulsion therapy for propafenone toxicity.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Fat Emulsions, Intravenous; Humans; Male; Middle Aged; | 2011 |
[Propafenone in the treatment of cardiac arrhythmias].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Propafenone | 2012 |
Successful treatment of suicide attempt by megadose of propafenone and captopril.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 2013 |
[Proarrhythmic effects of propafenone in a woman with hepatopathy: is it always a simple drug in clinical practice?].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Drug Therapy, Comb | 2002 |
Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cytochrome P-450 CYP2D6; Female; Genotype | 2002 |
Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts.
Topics: Animals; Anisotropy; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Elect | 2003 |
Effects of propafenone associated with propofol on myocardial contractility, heart rate, coronary flow, and the incidence of arrhythmia in isolated hearts of rats.
Topics: Anesthetics, Intravenous; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulatio | 2004 |
Acute toxicity of propafenone in a case of suicidal attempt.
Topics: Acute Disease; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Male; Poisoning; Propafe | 2004 |
Pilsicainide in breast milk from a mother: comparison with disopyramide and propafenone.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Breast Feeding; Disopyramide; Female; Humans; Lidocain | 2005 |
Urticaria-angioedema reaction caused by propafenone.
Topics: Angioedema; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Drug Hypersensitivity; Enalapril; | 2006 |
New drugs in the management of ventricular arrhythmias.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1984 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1981 |
[Drug therapy of arrhythmia in coronary cardiopathy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Cardiac Comp | 1983 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
[Electrophysiologic and anti-arrhythmia properties of propafenone deducible from experimental studies in vitro].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Dose-Response Relationship, Drug; Drug Evalua | 1984 |
[Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Elect | 1984 |
Worsening of arrhythmias during pharmacological treatment.
Topics: Adolescent; Adult; Aged; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzene | 1984 |
Drug therapy of cardiac arrhythmias.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Biological Availabili | 1983 |
[Relation between plasma levels of propafenone and its clinical efficacy in the treatment of patients with stabilized ventricular ectopic beats].
Topics: Arrhythmias, Cardiac; Drug Evaluation; Humans; Propafenone; Propiophenones | 1984 |
Electrophysiologic effects of propafenone on canine ischemic cardiac cells.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; El | 1984 |
[Hemodynamic effects of propafenone in acute myocardial infarct].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Hemodynamics; Humans; Male; Middle Aged; Myocard | 1984 |
[Electrophysiologic effects of propafenone in subjects with pre-existing excito-conduction disorders].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Conduction System; Heart Rate; Humans; M | 1984 |
[Propafenone in refractory supraventricular arrhythmias].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Female; Heart Ventricles | 1984 |
Propafenone for the treatment of severe ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dizziness; Female; Humans; Male; Middle A | 1984 |
Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Output; Central Ve | 1984 |
Epicardial, endocardial and transmural mapping in assessing electrophysiological effects of 14-C lidocaine and 14-C propafenone on activation times in experimental chronic myocardial infarction. Correlations with myocardial drugs concentrations.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbon Radioisotopes; Coronary Circulation; D | 1984 |
[Emergency treatment of arrhythmias in neonates and infants].
Topics: Arrhythmias, Cardiac; Bradycardia; Critical Care; Female; Heart Arrest; Heart Block; Heart Defects, | 1983 |
Clinical evaluation of new antiarrhythmic agents: experiences with propafenone.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Female; Hu | 1983 |
Problems of antiarrhythmic treatment in children.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Electrocardiography; Humans; Propaf | 1983 |
Propafenone disposition kinetics in cardiac arrhythmia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Half-Life; Humans; Kinetics; Male | 1984 |
New and old concepts in sarcoidosis.
Topics: Acetazolamide; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Prednisone; Prop | 1983 |
[Validity and limits of invasive pharmacological tests in the treatment of malignant ventricular hyperkinetic arrhythmias].
Topics: Adult; Aged; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Fe | 1983 |
[Propafenone: a new anti-arrhythmic drug for treatment of ectopic ventricular beats].
Topics: Adult; Aged; Arrhythmias, Cardiac; Humans; Male; Middle Aged; Propafenone; Propiophenones | 1982 |
[Propafenone: a new anti-arrhythmic agent for the treatment of ventricular ectopic beats].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Evalua | 1982 |
High-performance liquid chromatographic analysis of propafenone in human plasma samples.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Humans; Propafen | 1982 |
[The effect of disopyramide, mexiletine and propafenon after intravenous and oral administration on left ventricular function in the M-mode echocardiogram].
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Drug Therap | 1982 |
[Observations on the anti-arrhythmic effects of propafenone].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; | 1982 |
[Prolonged administration of propafenon in the treatment of premature ventricular beats. Evaluation by dynamic (Holter) electrocardiography].
Topics: Arrhythmias, Cardiac; Blood Pressure; Electrocardiography; Heart Rate; Humans; Propafenone; Propioph | 1980 |
[Action of propafenon hydrochloride in experimental ventricular arrhythmias induced by barium chloride].
Topics: Animals; Arrhythmias, Cardiac; Barium; Barium Compounds; Chlorides; Dogs; Electrocardiography; Femal | 1981 |
[Profile of a new anti-arrhythmic agent: propafenon. I. Electrophysiologic characterization].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Conduction System; Hu | 1981 |
[Study of the electrophysiologic effects of propafenon in patients with cardiac pre-excitation].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle | 1981 |
[Importance of programmed ventricular stimulation in the evaluation of proarrhythmic effects of orally administered anti-arrhythmia agents].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Arti | 1995 |
Clinical experience with propafenone for cardiac arrhythmias in the young.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Complexes, Premature | 1994 |
Lidocaine shows greater selective depression of depolarized and acidotic myocardium than propafenone: possible implications for proarrhythmia.
Topics: Action Potentials; Analysis of Variance; Animals; Arrhythmias, Cardiac; Female; Guinea Pigs; Heart; | 1993 |
Propafenone slows conduction and produces a nonuniform recovery of excitability between Purkinje and ventricular muscle fibers.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Electrophysiology; Heart; Heart Conduction System; | 1993 |
Chaotic atrial rhythm in children.
Topics: Amiodarone; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Electrocardiography, Ambulat | 1995 |
[The effects of propafenone in the treatment of ventricular arrhythmias with a malignant potential for resistance to conventional anti-arrhythmia medication].
Topics: Angina, Unstable; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Dr | 1993 |
[Tiracizine in the treatment of ventricular arrhythmia (preliminary study)].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dibenzazepines; Female; Heart Ventricles; Humans; Male | 1993 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
[The effect of treatment with propafenone, metoprolol and amiodarone on lymphocyte sodium efflux and level of cAMP in serum].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cyclic AMP; Female; Heart Dis | 1995 |
In vitro assessment of various cytochromes P450 and glucuronosyltransferases using the antiarrhythmic propafenone as a probe drug.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cyto | 1996 |
[Pharmaco-toxicologic evaluation of newly synthesized analogs of propafenone].
Topics: Adrenergic beta-Agonists; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1997 |
Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists.
Topics: Administration, Oral; Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Child, Presch | 1998 |
Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Confounding Factors, Epide | 1998 |
Recurrent convulsions and cardiac conduction disturbances after propafenone overdose.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Conduction System; Humans; Propaf | 1999 |
Diprafenone.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Inte | 1999 |
Giant inverted T waves.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Humans; Male; Myocardial Is | 2001 |
Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography; | 1992 |
[Efficacy and tolerance of propafenone in the prevention after a year of recurrent atrial arrhythmia. Results of a multicenter study of 114 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Blood Pressure; Drug Tolerance; El | 1992 |
Antiarrhythmic, electrophysiological and haemodynamic effects of prolonged oral dosing with Org 7797 in the anaesthetized rat.
Topics: Action Potentials; Administration, Oral; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, C | 1992 |
Effects of oral propafenone therapy on chronic myocardial pacing threshold.
Topics: Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Blo | 1992 |
Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Consciousness; Dogs; Electric Stimulation; El | 1992 |
[Anti-arrhythmia agents in heart failure].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; C | 1992 |
[Drug treatment of arrhythmia. Clinical experience with anti-arrhythmia preparation ritmonorm (propafenone)].
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Humans; Propafenone | 1992 |
Propafenone pharmacokinetics in uremic patients treated by peritoneal dialysis.
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Kidney Failure, Chronic; Middle Aged; Peritoneal Dialysi | 1992 |
Identification of propafenone metaboliser phenotype from plasma and urine excretion data.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Debrisoquin; Female; Humans; Hydroxylation; Ma | 1992 |
LG 6-101 and LG 6-102, two new propafenone-related antiarrhythmic agents with good oral activity in rats.
Topics: Aconitine; Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biological A | 1992 |
The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model.
Topics: Animals; Arrhythmias, Cardiac; Biotransformation; Chromatography, High Pressure Liquid; Male; Myocar | 1990 |
[Amiodarone and propafenone: evaluation using serial Holter recordings in patients with ventricular arrhythmia].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Electrocardiography, Am | 1990 |
Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Estrenes; Female; | 1991 |
[Correlation of signal-averaged electrocardiograms with the threatening ventricular arrhythmia during recovery period of experimental acute myocardial infarction].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Electrocardiography; Heart Ventricles; My | 1991 |
Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography | 1991 |
Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG).
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocar | 1991 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Chi-Square Distribution; Chi | 1991 |
[Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
Topics: Adult; Aged; Arrhythmias, Cardiac; Female; Humans; Liver; Male; Middle Aged; Oxidation-Reduction; Pr | 1991 |
Raised serum levels of desipramine with the antiarrhythmic propafenone.
Topics: Aged; Arrhythmias, Cardiac; Depressive Disorder; Desipramine; Drug Interactions; Humans; Male; Propa | 1991 |
From the National Institutes of Health.
Topics: Acute Disease; ADP Ribose Transferases; Amoxicillin; Arrhythmias, Cardiac; Bacterial Toxins; Cardiom | 1991 |
Antiarrhythmic effects of two new propafenone related drugs. A study on four animal models of arrhythmia.
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Female; Guinea P | 1991 |
Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Chi-Square Distribution; Dose-Response Relatio | 1991 |
[Propafenone--a promising anti-arrhythmia agent?].
Topics: Arrhythmias, Cardiac; Humans; Propafenone | 1990 |
Ciclosporin-propafenone interaction.
Topics: Arrhythmias, Cardiac; Creatinine; Cyclosporins; Drug Interactions; Heart Transplantation; Humans; Ma | 1990 |
Interaction between digoxin and propafenone in children.
Topics: Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Creatinine; Digoxin; Drug Interactions; D | 1990 |
[Arrhythmia in children. Report of the round table "10 years of Rytmonorm in Pediatrics". Wiesbadeu, 3 March 1990].
Topics: Arrhythmias, Cardiac; Child; Humans; Propafenone | 1990 |
Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Dogs; Epinephrine; Female; | 1985 |
[Propafenone in ventricular hyperkinetic arrhythmias. Dynamic ECG evaluation of the acute oral test and short-term treatment].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bundle-Branch Block; Cardiac Complexes, Prematur | 1986 |
[Propafenone: evaluation of antiarrhythmic efficacy in hyperkinetic ventricular arrhythmia using acute oral test].
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluati | 1988 |
Propafenone monitoring in patients with refractory ventricular arrhythmias.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Drug Resistance | 1989 |
[Medium term study of the efficacy of propafenone in the treatment of hyperkinetic ventricular arrhythmia].
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle | 1989 |
[Use of propafenone in emergency therapy].
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiograp | 1989 |
Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Dru | 1985 |
Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
Topics: Adult; Animals; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Dogs; Electrophysiology; | 1989 |
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
Topics: Adult; Aged; Arrhythmias, Cardiac; Biotransformation; Electrocardiography; Female; Humans; Hydroxyla | 1989 |
[Propafenone on the way into a new world. Profile of the anti-arrhythmia agent].
Topics: Arrhythmias, Cardiac; Heart Ventricles; Humans; Propafenone | 1989 |
[Changes in thrombocyte-vascular hemostasis and cyclic nucleotide levels after anti-arrhythmia therapy in patients with ischemic heart disease].
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Female; Humans; Male; Mexiletine; | 1989 |
[10 years' experience with rytmonorm. Round table discussion. 27 May 1989, Munich. Abstracts].
Topics: Arrhythmias, Cardiac; Humans; Propafenone | 1989 |
[Control of the efficacy of anti-arrhythmia drug therapy with the ambulatory electrocardiogram. Proposal for a new analytical statistical model].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Huma | 1985 |
Lack of clinically significant beta-blocking effect of propafenone.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Electroc | 1987 |
Newer antiarrhythmic drugs in children.
Topics: Adolescent; Adult; Amiodarone; Anilides; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardi | 1987 |
Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Di | 1987 |
[Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Female; Follow-Up Studies; Humans; | 1987 |
[Worsening of ventricular arrhythmia in the dynamic ECG in patients treated with anti-arrhythmia drugs].
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Therapy, Com | 1988 |
[New antiarrhythmia agents: propafenone and flecainide].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Flecainide; He | 1985 |
Are different pharmacokinetic properties of lidocaine versus propafenone in normal as compared to ischemic myocardium responsible for different electrophysiologic effects which help preventing arrhythmias?
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Electrophysiology; Guinea Pigs; In Vitro Techni | 1988 |
Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient.
Topics: Adult; Arrhythmias, Cardiac; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Pro | 1988 |
[Propafenone. An antiarrhythmic agent for both ventricular and supraventricular arrhythmia].
Topics: Arrhythmias, Cardiac; Heart Ventricles; Humans; Propafenone; Tachycardia, Supraventricular | 1988 |
Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Guinea Pigs; Heart; In Vit | 1988 |
Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2-year experience.
Topics: Aged; Arrhythmias, Cardiac; Chronic Disease; Drug Administration Schedule; Electrocardiography; Huma | 1988 |
Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.
Topics: Acetylcholine; Animals; Arrhythmias, Cardiac; Autonomic Nervous System; Dogs; Female; Heart Conducti | 1988 |
[Arrhythmias in the rehabilitation period after myocardial revascularization surgery by aortocoronary bypass. Efficacy of anti-arrhythmia therapy with propafenone].
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocar | 1986 |
Sustained ventricular tachycardia occurring during propafenone therapy.
Topics: Arrhythmias, Cardiac; Electrocardiography; Heart Ventricles; Humans; Male; Middle Aged; Propafenone; | 1987 |
[Propafenone as an anti-arrhythmia agent].
Topics: Arrhythmias, Cardiac; Drug Evaluation; Heart Conduction System; Humans; Propafenone | 1986 |
[Evaluation of the efficacy of propafenone in rhythm disorders in childhood using Holter monitoring].
Topics: Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography; Female; Humans; Male | 1987 |
Antiarrhythmic effects of a novel diamine derivative, AN-132, on several animal models of cardiac arrhythmias.
Topics: Aconitine; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chloroform; Disopyramide | 1987 |
[Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Female; Humans; Male; Mi | 1987 |
Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Chemical Phenomena; Chemis | 1987 |
[Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy].
Topics: Aged; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Heart Ventricles; Humans; Male; M | 1987 |
Hemodynamic and electrophysiologic effects of combined infusion of lidocaine and propafenone in humans.
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrophysiology; Female; Hemodynamics; Humans; Injections, Intr | 1987 |
[Oral propafenone in refractory arrhythmia. Apropos of 68 patients].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Age | 1986 |
An experimental approach to the choice of antiarrhythmic therapy.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Diltiazem | 1986 |
[Oral propafenone in the long-term treatment of chronic ventricular arrhythmia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Female; Hear | 1986 |
[Evaluation of the hemodynamic effects and anti-arrhythmic activity of propafenone: from new frontiers to clinical verification].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Hemodynamics; Humans; Propafenone; Propiophenones | 1986 |
[Propafenone in the treatment of high-risk ventricular arrhythmias].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Ventricles; Humans; Male; Middle | 1986 |
[Low-dose propafenone in chronic ventricular arrhythmia: evaluation by linear regression analysis and correlation with the plasma concentrations of the drug].
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Female; Humans; Kinetics; Male; Middle Aged; Pro | 1986 |
Short- and long-term effects of propafenone in ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Drug Administration Schedule; Electrocardiography; Fe | 1986 |
Ventricular parasystole and ventricular couplets: a re-entry within the parasystolic focus?
Topics: Arrhythmias, Cardiac; Electrocardiography; Humans; Male; Middle Aged; Myocardial Contraction; Procai | 1987 |
[Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Drug Interactions; Drug Therapy, Co | 1986 |
[Therapy of severe propafenone poisoning--an attempt at elimination by hemoperfusion].
Topics: Adult; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Electrocardiography; Female; Hemo | 1986 |
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cytochrome P-450 CYP2D6; Debrisoquin; Dose-Response Relationship, | 1987 |
[Oral propafenone in chronic ventricular arrhythmias. Prospective evaluation with the Holter monitor].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Heart Ventricles | 1985 |
Aggravation of ventricular arrhythmia. A drug-induced complication.
Topics: Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; El | 1985 |
[The anti-arrhythmic effects and electrophysiological actions of propafenone].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Female; Heart; Humans; Male; Propaf | 1985 |
Use of short-term drug testing as part of a systematic approach for evaluation of antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electric Stimulation; Humans; Monitor | 1986 |
Suppression of premature ventricular contractions: we can, but should we?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Ventricles; Humans; Propafenone; Propiophenones | 1986 |
Propafenone for the treatment of refractory complex ventricular ectopic activity.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Ev | 1986 |
A method for evaluating different modes of action of an antiarrhythmic drug in man. The effects of propafenone on sinus nodal functions.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atropine; Autonomic Nervous S | 1985 |
Metabolite cumulation during chronic propafenone dosing in arrhythmia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Aged; Propaf | 1985 |
[The treatment of arrhythmias in infants and children using propafenone].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Child, Preschool; Drug Administration Schedule; | 1985 |
Propafenone.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Propafenone; Propiophenones | 1985 |
Malignant ventricular tachyarrhythmias in association with propafenone treatment.
Topics: Adult; Aged; Arrhythmias, Cardiac; Death, Sudden; Electrocardiography; Humans; Male; Middle Aged; Pr | 1985 |
The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias.
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Female; Heart Arres | 1985 |